Stem Cells Therapy May Provide Diabetes Treatment
Diabetes patients may benefit from receiving treatment from a groundbreaking research that transfers human embryonic stem cells into insulin releasing cells. The research was conducted by San Diego based biological company Novocell on mice.
Scientists inserted human embryonic stem cells into mice with artificially posed diabetes like symptoms. The mice showed to be developing insulin releasing cells thanks to inserted embryos.
Type 1 diabetes patients have damaged pancreatic beta cells that are responsible for insulin release. Insulin is being released in response to blood glucose to regulate the levels of sugar in body.
Novocell have already conducted successful researchers in forming pancreas and endocrine cells for producing hormones thanks to human embryonic stem cell therapy. This new research enables growth of insulin releasing cells and shows promise for diabetes patients. Apart from stem cell producing, Novocell also develops ways to implant those cells into patients without much hurting their health.
"Our data provide the first compelling evidence that human embryonic stem cells can serve as a renewable source of functional insulin producing cells for diabetes cell replacement therapies," said Emmanuel Baetge, Ph.D., Chief Scientific Officer of Novocell. "It also provides strong evidence that human embryonic stem cell-derived endoderm cells are able to generate glucose-responsive insulin secreting cells that are functionally similar to adult human beta cells."
Current diabetes cellular treatment is being handled by donor pancreatic islets. These cell are being transplanted into patients pancreas and start releasing insulin. However, this treatment is not that efficient because lack of donors and side effects.